Synlogic selects AbbVie as First Corporate Partner; Synlogic Terminates Agreement
Under a multi-year deal, Synlogic Inc. and AbbVie Inc. are teaming up to develop new microbiome therapies for inflammatory bowel diseases including Crohn’s disease and ulcerative colitis.
- Drug Discovery Tools
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.